AI Article Synopsis
- Lassa fever (LF) is a viral disease with potential for widespread outbreaks, and there are currently no licensed vaccines available.
- A scoping review was conducted to analyze registered clinical trials for LF vaccine candidates, focusing on phases 1, 2, and 3.
- Four vaccine candidates have reached clinical trials, with five phase 1 trials and one phase 2 trial registered, indicating promising progress towards developing a safe and effective vaccine.
Article Abstract
Objective: Lassa fever (LF) is caused by a viral pathogen with pandemic potential. LF vaccines have the potential to prevent significant disease in individuals at risk of infection, but no such vaccine has been licensed or authorised for use thus far. We conducted a scoping review to identify and compare registered phase 1, 2 or 3 clinical trials of LF vaccine candidates, and appraise the current trajectory of LF vaccine development.
Method: We systematically searched 24 trial registries, PubMed, relevant conference abstracts and additional grey literature sources up to 27 October 2022. After extracting key details about each vaccine candidate and each eligible trial, we qualitatively synthesised the evidence.
Results: We found that four LF vaccine candidates (INO-4500, MV-LASV, rVSV∆G-LASV-GPC, and EBS-LASV) have entered the clinical stage of assessment. Five phase 1 trials (all focused on healthy adults) and one phase 2 trial (involving a broader age group from 18 months to 70 years) evaluating one of these vaccines have been registered to date. Here, we describe the characteristics of each vaccine candidate and trial and compare them to WHO's target product profile for Lassa vaccines.
Conclusion: Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247453 | PMC |
| http://dx.doi.org/10.1111/tmi.13876 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: We aim to repurpose the widely used adjuvant and immunomodulator Alhydrogel at a specific dose and schedule (AD04) as a disease-modifying treatment for mild Alzheimer's disease (AD). AD04 is a potent adjuvant commonly used in vaccines and allergy immunotherapies to augment the magnitude and durability of the immune response. Our preliminary data come from a clinical Phase 2 study in which AD04 served as a control arm.
View Article and Find Full Text PDFA universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein.
Vaccine
January 2025
College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, Jiangsu, China; Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China; Joint International Research Laboratory of Agriculture and Agri-Product Safety, Yangzhou University (JIRLAAPS), Yangzhou, China. Electronic address:
Streptococcus suis (S. suis) is a major pathogen that poses a long-term threat to swine populations. Due to its foodborne transmission, this pathogen has recently emerged as a leading cause of meningitis in humans, presenting a significant public health challenge.
View Article and Find Full Text PDFChildhood Tuberculosis-Advances in Treatment and Prevention.
Pediatr Pulmonol
January 2025
Department of Child Health School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Tuberculosis (TB) in childhood presents a substantial global burden with nearly two million episodes of disease in children and adolescents annually. The majority of children who die from TB never receive appropriate treatment. Advancements in childhood TB treatments have been slow and there are many challenges with TB treatment in children.
View Article and Find Full Text PDFPrevention of Infections Among Pediatric Solid Organ Transplant Recipients With Asplenia or Hyposplenism.
Pediatr Transplant
February 2025
Department of Pediatrics, Division of Infectious Diseases, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Pediatric solid organ transplant (SOT) recipients with splenic dysfunction are at increased risk for infections, and tailored guidance on the management of asplenia/hyposplenism among SOT recipients is often lacking. The purpose of this article is to provide practice recommendations via a frequently asked questions (FAQs) format that focuses on three main domains: the identification of asplenia/hyposplenism among SOT recipients/candidates, prophylactic strategies for mitigating the risk of invasive disease associated with splenic dysfunction in the context of transplantation, and the provision of appropriate patient counseling on the risks associated with asplenia/hyposplenism. Answers to the FAQs are based on international expert opinion informed by practices for managing splenic dysfunction and associated data in other populations with asplenia.
View Article and Find Full Text PDFMpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
School of Human Sciences, London Metropolitan University, London, UK.
Mpox, formerly known as monkeypox, is a zoonotic disease caused by the Mpox virus (MPXV), which has recently attracted global attention due to its potential for widespread outbreaks. Initially identified in 1958, MPXV primarily spreads to humans through contact with infected wild animals, particularly rodents. Historically confined to Africa, the virus has expanded beyond endemic regions, with notable outbreaks in Europe and North America in 2022, especially among men who have sex with men (MSM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!